Effects of diverse nutrient on intestinal biologic barrier of patients with active ulcerative colitis

doi:10.3969/j.issn.1006-7795.2019.04.025

Abstract

Abstract: Objective To evaluate the intervene effect of diverse nutrient on intestinal biologic barrier and the feasibility of applying diverse nutrient recipe in patients with acute ulcerative colitis (UC). Methods Totally 79 patients enrolled were randomly assigned to five groups, traditionary group (T-group), enteral nutrition group (E-group), microecologicalagent group (ME-group), immunostimulants group (IS-group), immune-enhanced enteral nutrition group (IEEN-group). Germiculture was used to detect the stool of all subjects before and after treatment, and the number of Bacterium lacticum,Bifidobacterium, Enterococci, Entericbacilli and yeasts were counted, then to compare the differences of intestinal flora composition and observe the remission situation. Results The clinical efficacy of the IEEN-group was better than that in the T-group. The improvement of intestinal flora of the IEEN-group was the best, then the E-group, then the ME-group and IS-group, the T-group was the last. The IEEN-group and the E-group may be beneficial to UC patients. Conclusion Application of different nutrient formulations in patients with active ulcerative colitis can improve the intestinal flora imbalance and protect intestinal barrier in patients with active ulcerative colitis.

Key words: ulcerative colitis, enteral nutrition, Gln, probiotic, flora analysis

CLC Number:

R574.62

Wu Huibo, Zhao Haiying, Zhu Shengtao, Wu Yongdong, Zhang Shutian. Effects of diverse nutrient on intestinal biologic barrier of patients with active ulcerative colitis[J]. Journal of Capital Medical University, 2019, 40(4): 635-639.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.04.025

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I4/635

References 19

[1]	Eccles M, Clapp Z, Grimshaw J, et al. North of England evidence based guidelines development project:methods of guideline development[J]. BMJ, 1996, 312(7033):760-762.
[2]	Hermsen J L, Gomez F E, Maeshima Y, et al. Decreased enteral stimulation alters mucosal immune chemokines[J]. JPEN J Parenter Enteral Nutr,2008, 32(1):36-44.
[3]	Kang W, Kudsk K A. Is there evidence that the gut contributes to mucosal immunity in humans[J]? JPEN J Parenter Enteral Nutr, 2007, 31(3):246-258.
[4]	Goldberg R F, Austen W G Jr, Zhang X, et al. Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition[J]. Proc Natl Acad Sci U S A, 2008, 105(9):3551-3556.
[5]	Cruzat V, Macedo Rogero M, Noel Keane K, et al. Glutamine:metabolism and immune function, supplementation and clinical translation[J]. Nutrients, 2018, 10(11):pii:E1564.doi:10.3390.nu10111564.
[6]	Yang X, Twitchell E, Li G, et al. High protective efficacy of rice bran against human rotavirus diarrhea via enhancing probiotic growth, gut barrier function, and innate immunity[J]. Sci Rep, 2015, 5:15004.
[7]	Baumgart D C, Carding S R. Inflammatory bowel disease:cause and immunobiology[J]. Lancet,2007, 369(9573):1627-1640.
[8]	Xavier R J, Podolsky D K. Unravelling the pathogenesis of inflammatory bowel disease[J]. Nature,2007, 448(7152):427-434.
[9]	Becker C, Neurath M F, Wirtz S. The intestinal microbiota in inflammatory bowel disease[J]. ILAR J, 2015, 56(2):192-204.
[10]	Sandborn W J, Feagan B G, Hanauer S B, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease[J]. Gastroenterology,2002,122(2):512-530.
[11]	Ockenga J, Borchert K, Stüber E, et al. Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease[J]. Eur J Clin Nutr,2005, 59(11):1302-1309.
[12]	Feng D, Xu W, Chen G, et al. Influence of glutamine on intestinal inflammatory response, mucosa structure alterations and apoptosis following traumatic brain injury in rats[J]. J Int Med Res,2007, 35(5):644-656.
[13]	Bengmark S. Bio-ecological control of acute pancreatitis:the role of enteral nutrition, pro and synbiotics[J]. Curr Opin Clin Nutr Metab Care, 2005, 8(5):557-561.
[14]	陈琳琳,郑倩. 嗜酸乳酸杆菌对实验性溃疡性结肠炎治疗的最佳浓度探索及免疫学机制初探[J]. 川北医学院学报, 2017, 32(3):339-343.
[15]	Matsumoto S, Hara T, Hori T, et al. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells[J]. Clin Exp Immunol, 2005, 140(3):417-426.
[16]	张永利,申妮. 溃疡性结肠炎患者肠道菌群的变化特征[J]. 河北医药,2018, 40(7):1054-1057.
[17]	刘志威,王学群,李甜甜. 溃疡性结肠炎患者肠道菌群变化的临床意义[J].胃肠病学和肝病学杂志,2016, 25(5):554-556.
[18]	厉娜娜,郝微微,温红珠,等. 肠道菌群与溃疡性结肠炎[J]. 辽宁中医药大学学报, 2013, 15(11):101-103.
[19]	梅晨雪, 王恩铭扬, 孙妍, 等. 英夫力西治疗炎症性肠病与肠道菌群改变的相关性研究[J]. 实用药物与临床, 2017, 20(4):394-397.